NewEdge Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

NewEdge Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-3,054	Closed	-$274K	–	955
2020 Q1	$274K	Buy	+3,054	New	+$300K	0.01%	625

Other funds holding ALXN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

NewEdge Advisors's ALXN Position: Q2 2020 in Review

NewEdge Advisors sold out of Alexion Pharmaceuticals (ALXN) in Q2 2020, closing a stake of 3,054 shares — an estimated $274K sold.

NewEdge Advisors first reported a position in ALXN in Q1 2020 and held it in 1 quarter. The position peaked at $274K in Q1 2020. 705 funds tracked by Wall St. Rank hold ALXN as of Q2 2020.

NewEdge Advisors reported no remaining Alexion Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
NewEdge Advisors sold 3,054 Alexion Pharmaceuticals shares in Q2 2020, an estimated $274K.
NewEdge Advisors first reported a position in Alexion Pharmaceuticals in Q1 2020 and held it in 1 quarter.
NewEdge Advisors's Alexion Pharmaceuticals position peaked at $274K in Q1 2020.
705 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2020.

Based on NewEdge Advisors's 13F filing for Q2 2020, filed 29 Jul 2020.